Monday, May 14, 2012

ONO-2745/CNS 7056 shows positive data in Phase 2 trial for inducing and maintaing general anesthesia

In an open-label study in surgery patients (Japan),  undergoing general anesthesia in combination with analgesics, ONO-2745/CNS 7056 was intravenously administered to 85 surgery patients (> 20 years).
45 patients were administered ONO-2745/CNS 7056  with a purpose to induce general  anesthesia, while 40patients were give ONO-2745/CNS 7056 for induction and maintenance of general anesthesia.

All 43 patients analyzed among the patients who received ONO-2745/CNS 7056 for induction of general anesthesia achieved loss of consciousness and underwent successful intubation, while all 32 patients analyzed among the patients who received ONO-2745/CNS 7056 for induction and maintenance of general anesthesia achieved loss of consciousness and underwent successful intubation with successful completion of a surgery without need of rescue therapy for sedative effects.

No adverse events of concern were observed

ONO-2745/CNS 7056 is an innovative short-acting benzodiazepine derivative, which binds to the binding site of the GABA receptors*, enhancing binding of GABA to its binding site to increase function of GABA receptors, which leads to the onset of sedative effects.ONO entered into a license agreement with PAION (formerly CeNeS) in August 2007, acquiring the exclusive rights to develop and market ONO-2745/CNS 7056 in Japan.  PAION is headquartered in Aachen, Germany and has a second site in Cambridge, UK. The company is specialised in developing innovative drugs for the hospital-based treatment in indications for which there is a substantial unmet medical need

Source - Ono Pharmaceuticals new release